Across TCGA pan-cancer cohorts, NDUFA4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NDUFA4 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher NDUFA4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NDUFA4 expression acts as an unfavorable survival marker.

BLCA and LIHC are the cancer types where NDUFA4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.152	0.625	.012	18	view →
LIHC	DFS	Median	All	0.096	0.526	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: NDUFA4 tumor-vs-normal RNA expression · all NDUFA4 data types